Cognition Therapeutics (CGTX) Income towards Parent Company (2020 - 2026)
Cognition Therapeutics (CGTX) reported Income towards Parent Company of -$8.8 million for Q1 2026, up 35.98% year-over-year from -$6.5 million in Q1 2025, and up 35.49% on a QoQ basis from -$13.7 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Income towards Parent Company data on file, last reported at -$8.8 million in Q1 2026.
- Quarterly Income towards Parent Company rose 35.98% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.9 million (up 20.14% YoY) and the FY2025 annual result came in at -$47.8 million, down 40.74% from the prior year.
- Income towards Parent Company grew to -$8.8 million in Q1 2026 per CGTX's latest filing, from -$13.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$3.8 million in Q1 2022 and bottomed at -$15.2 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$12.6 million (2022), against an average of -$10.8 million.
- The widest annual swing landed in 2022, when Income towards Parent Company tumbled 1821.08%; it then soared 55.93% in 2025.
- Tracing CGTX's Income towards Parent Company over 5 years: stood at -$9.3 million in 2022, then tumbled by 63.42% to -$15.2 million in 2023, then gained by 29.41% to -$10.7 million in 2024, then retreated by 27.48% to -$13.7 million in 2025, then surged by 35.49% to -$8.8 million in 2026.
- Per Business Quant, the three latest CGTX Income towards Parent Company figures stand at -$8.8 million (Q1 2026), -$13.7 million (Q4 2025), and -$6.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.82 Mn |
| Dec 31, 2025 | -13.68 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | -13.78 Mn |
| Dec 31, 2024 | -10.73 Mn |
| Sep 30, 2024 | -14.47 Mn |
| Jun 30, 2024 | -14.69 Mn |
| Mar 31, 2024 | -14.11 Mn |
| Dec 31, 2023 | -15.20 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -4.73 Mn |
| Mar 31, 2023 | -6.17 Mn |
| Dec 31, 2022 | -9.30 Mn |
| Sep 30, 2022 | -12.63 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.84 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -5.22 Mn |
| Jun 30, 2021 | -1.49 Mn |
| Mar 31, 2021 | 223,000.00 |
| Dec 31, 2020 | -4.12 Mn |
| Sep 30, 2020 | -4.46 Mn |